All NICE products on neuropathic and persistent pain. Includes any guidance, advice, NICE Pathways and quality standards.
Everything NICE has said on pharmacological management of neuropathic pain in adults in non-specialist settings in an interactive flowchart
This guideline covers managing neuropathic pain (nerve pain) with pharmacological treatments (drugs) in adults in non-specialist settings. It aims to improve quality of life for people with conditions such as neuralgia, shingles and diabetic neuropathy by reducing pain and promoting increased participation in all aspects of daily living. The guideline sets out how drug treatments for neuropathic pain differ from traditional pain management.
Evidence-based recommendations on percutaneous electrical nerve stimulation (PENS) for refractory neuropathic pain
Evidence-based recommendations on transcranial MRI-guided focused ultrasound thalamotomy for neuropathic pain in adults
Evidence-based recommendations on the Senza spinal cord stimulation system for delivering HF10 therapy to treat chronic neuropathic pain
Evidence-based recommendations on spinal cord stimulation (SCS) for chronic pain of neuropathic or ischaemic origin in adults
This guideline covers managing acute and chronic pancreatitis in children, young people and adults. It aims to improve quality of life by ensuring that people have the right treatment and follow-up, and get timely information and support after diagnosis.
This guideline covers the diagnosing and managing of myeloma (including smouldering myeloma and primary plasma cell leukaemia) in people aged 16 and over. It aims to improve care for people with myeloma by promoting the most effective tests and treatments for myeloma and its complications.
This guideline covers diagnosing and managing endometriosis. It aims to raise awareness of the symptoms of endometriosis, and to provide clear advice on what action to take when women with signs and symptoms first present in healthcare settings. It also provides advice on the range of treatments available.
pharmacological drugs for neuropathic pain:- Is there a potential for dependence associated with pharmacological agents for...
Recommendation ID NG41/1 Question Neuropathic pain relief:- Does early treatment with a centrally acting analgesic (for example...
This guideline covers assessing and managing low back pain and sciatica in people aged 16 and over. It outlines physical, psychological, pharmacological and surgical treatments to help people manage their low back pain and sciatica in their daily life. The guideline aims to improve people’s quality of life by promoting the most effective forms of care for low back pain and sciatica.
Question Monotherapy versus combination therapy for treating neuropathic pain:- What is the clinical effectiveness, cost effectiveness...
This document summarises the evidence base on medicines optimisation in chronic pain . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .
Evidence-based recommendations on deep brain stimulation (DBS) for refractory chronic pain syndromes (excluding headache)
support, that influence participation and quality of life in people with neuropathic pain? Any explanatory notes(if applicable) Why this...
CG173/2 Question Relationship between symptoms, cause of neuropathic pain and its treatment:- Is response to pharmacological treatment...
of life in neuropathic pain? Any explanatory notes(if applicable) Why this is important:- Pharmacological agents for neuropathic...
into percutaneous electrical nerve stimulation (PENS) for refractory neuropathic pain, particularly to provide more information about...
For adults with fibromyalgia or persistent treatment-resistant neuropathic pain, what is the clinical and cost effectiveness of...
Evidence-based recommendations on laparoscopic uterine nerve ablation (LUNA) for treating chronic pelvic pain
Summary of the evidence on oral ketamine for treating chronic pain to inform local NHS planning and decision-making
also used outside of its product licence (off-label use) for treating neuropathic pain, migraine, depression and dementia. If valproate...
This guideline covers diagnosing and managing multiple sclerosis in people aged 18 and over. It aims to improve the quality of life for adults with multiple sclerosis by promoting symptom management, comprehensive reviews and effective relapse treatment.
Everything NICE has said on systems and processes to develop, authorise, use, and update patient group directions in an interactive flowchart
NICE Medicines and technologies programme: adoption team
This guideline covers stroke rehabilitation for adults and young people aged 16 and over who have had a stroke with continuing impairment, activity limitation or participation restriction. It aims to improve rehabilitation for people who have had a stroke by specifying how stroke units and multidisciplinary stroke teams should be organised. It makes detailed recommendations on assessments and interventions for the functional difficulties caused by stroke.
This guideline covers the assessment and early management of spinal column and spinal cord injury in pre-hospital settings (including ambulance services), emergency departments and major trauma centres. It covers traumatic injuries to the spine but does not cover spinal injury caused by a disease.It aims to reduce death and disability by improving the quality of emergency and urgent care.
This guideline covers the planning and management of end of life and palliative care in for infants, children and young people (aged 0–17 years) with life-limiting conditions. It aims to involve children, young people and their families in decisions about their care, and improve the support that is available to them throughout their lives.
This guideline covers the initial assessment of symptoms and signs that might indicate a neurological condition. It helps non-specialist healthcare professionals to identify people who should be offered referral for specialist investigation.
Everything NICE has said on low back pain and sciatica in an interactive flowchart
Question For children and young people with intractable cancer-related pain and pain associated with specific diseases...
guidance. Source guidance details Comes from guidance Neuropathic pain in adults: pharmacological management in non-specialist settings
Everything NICE has said on assessing and managing upper aerodigestive tract cancer in young people and adults in an interactive flowchart
This document summarises the evidence base on suicide prevention: optimising medicines and reducing access to medicines as a means of suicide . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .
This guideline covers good practice for developing, authorising, using and updating patient group directions. It also offers advice on deciding whether a patient group direction is needed.
This guideline covers the care and treatment of adults (aged 18 and over) with type 1 diabetes.
This guidance has been updated and replaced by NICE guideline CG173.
This guideline covers preventing and managing foot problems in children, young people and adults with diabetes. It aims to reduce variation in practice, including antibiotic prescribing for diabetic foot infections.
Everything NICE has said on assessing and managing recent suspected cardiac chest pain including acute coronary syndromes and stable angina in an interactive flowchart
This guideline covers the care and management of type 2 diabetes in adults (aged 18 and over). It focuses on patient education, dietary advice, managing cardiovascular risk, managing blood glucose levels, and identifying and managing long-term complications.
CG143/1 | Pain management for patients with an acute painful sickle cell episode:- For patients
devices 1068 / 1 Intramuscular elec stimulation for post stroke shoulder pain Monitor - no CE marked devices 1086 / 1...
NICE technology appraisal guidance static list
Details of former NICE fellows
NICE has today (28 March) published a summary for healthcare professionals bringing together all its recommendations and other safety advice on the drug valproate.